Experimental aspects of NPY-decorated gold nanoclusters using randomized hybrid design against breast cancer cell line.

Drashti Desai, Pravin Shende

Journal: Biotechnology journal 2021;16(12):e2100319

PMID: 34595845

Abstract

Gold nanoclusters (AuNCs) are potential carrier system for bioactive like proteins and peptides used in various therapeutics against various ailments. Neuropeptide Y (NPY) is consists of 36 amino acids used to treat depression, obesity, epilepsy, and so on. but possess instability at higher temperatures causing its limited usage. The present study focused on the NPY-decorated AuNCs prepared using desolvation reduction technique and optimized through randomized hybrid design. ATR-FTIR, H NMR and CD spectroscopic studies confirmed the AuNCs structure interaction with NPY. The optimized NPY-decorated AuNCs possessed 85.6 ± 2.08% of entrapment efficiency with 85.32 ± 7.55% of NPY release for 24 h. It displayed dose-dependent cell cytotoxicity, IC value of 0.7 ± 0.05 μg mL and apoptosis of 68.48 ± 7.35% with controlled cell migration causing G0G1 cell arrest by penetrating cancer cell membrane on MCF-7 cell line. Furthermore, the AuNCs caused surface disruption of the cancerous cell further interrupting the protein synthesis by MAPK pathway leading to cell death. The AuNCs were stable for 3 months at 25 ± 2°C due to steric hindrance. Hence, NPY-decorated AuNCs were found to be effective on MCF-7 cell line with a significant anti-apoptotic effect, further emerging as a novel therapeutic delivery system in the management of breast cancer.

© 2021 Wiley-VCH GmbH.

Address: Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM'S NMIMS, Mumbai, Maharashtra, India.

Link outs

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.